DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Astrazeneca von "Hold" auf "Sell" abgestuft und das Kursziel von 11000 auf…
68,280$
-7,63%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Deutsche Bank Research senkt Astrazeneca auf Sell
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Astrazeneca von "Hold" auf "Sell" abgestuft und das Kursziel von 11000…
AstraZeneca: Herabstufung
Stockholm (www.aktiencheck.de) - Rating-Update:
Die Analysten von Nordea stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London…
AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
…
GOLDMAN SACHS stuft ASTRAZENECA auf Buy
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 15914 Pence…
Blue chips dragged by AstraZeneca, Apple iPhone 16 met with a shrug By Proactive Investors
Blue chips dragged by AstraZeneca, Apple iPhone 16 met with a shrug…
FTSE 100 dips as AstraZeneca weighs, Centamin takeover lifts precious metals miners
The FTSE 100 dipped on Tuesday as AstraZeneca weighed on the index after announcing disappointing developments for a lung cancer…
AstraZeneca Defends China Compliance In Wake of Staff Detentions
AstraZeneca Plc has strong compliance policies in China and is working closely with authorities following the detention of several employees…
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant…
AstraZeneca shares down on disappointing drug trial results By Investing.com
AstraZeneca shares down on disappointing drug trial results…